Facebook
Twitter
LinkedIn
Forward
Pinning Down Presbyopia: Optimizing Patient Selection and Pharmaceutical Management (CE Monograph)
Activity Description and Purpose
Presbyopia causes functional limitations beyond near blur and results in decreased vision-targeted health-related quality of life. Correction of presbyopia can improve health-related quality of life. Pharmacologic options for addressing presbyopia have recently entered clinical practice with the approval of 2 miotic eye drops. This educational activity provides an update on the clinical trials supporting the new pharmacologic approaches as well as clinical insights from experts on selecting and counseling appropriate patients. The desired results of this educational activity are to improve optometrists’ ability to appropriately incorporate pharmacologic drops in the management of their patients with presbyopia.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review clinical efficacy and safety data of approved miotics to treat presbyopia
- List characteristics that would indicate a patient is an appropriate or inappropriate candidate for pharmacologic treatments for presbyopia
- Obtain retinal examinations for all patient candidates for pharmacologic treatments for presbyopia
- Apply evidence to appropriately use pharmacologic treatments for presbyopia in a variety of patients
Faculty
 | Paul Karpecki, OD, FAAO (Chair) |
 | Selina McGee, OD, FAAO Visionary Founder and CEO BeSpoke Vision Edmond, Oklahoma Adjunct Faculty Northeastern State University Oklahoma College of Optometry Tahlequah, Oklahoma |
 | Rishi P. Singh, MD, FASRS
|
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any ineligible company. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
Paul Karpecki, OD, is a consultant for AbbVie Inc, AdOM Optical Technologies Ltd, AesculaTech*, AI Optics, Alcon, Aldeyra Therapeutics, Aramis Biosciences, Atlas Medical GmbH, Aurion Biotechnologies*, Azura Ophthalmics, Barti, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx, Brill Pharma, Bruno Vision, Cambium Bio Limited, Derma Cautery, Dompé US, Inc, Essilor of America, Inc, Eye Cool, Eyenovia, Inc*, Grifols, Harrow, Inc, Hilco Vision, iCare USA Inc, Kala Pharmaceuticals, Lentechs, LKC Technologies, Inc, Lexitas, OASIS Medical, Oculis, OCULUS, Inc, OCuSOFT Inc, Orasis Pharmaceuticals, Rendia, Inc, RxSIGHT, Samsara Vision, Inc, ScienceBased Health, Scope, Sentiss Pharma Pvt Ltd, Sight Sciences, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Sydnexis Inc, Tarsus Pharmaceuticals, Inc, Théa Pharma Inc, Topcon Medical Systems, Inc, Tracey Technologies, Vial*, ViaLase, Inc, Viatris Inc*, Visus Therapeutics, Vital Tears LLC, WebMD LLC, and Zeiss; is on the speakers bureau for Mallinckrodt; has stock options that have not been exercised in Able Therapeutics, Danelli Ocular Creations LLC, Essential Biologics, Inc, Eyedaptic Inc, Eyedetec Medical, Harrow, Inc, Healthe, Hue.AI, iVeena Delivery Systems, Lubris Biopharma, Neurolens, Omega Ophthalmics, Percept, Regener-Eyes, Signal 12 Inc, Silk Technologies Ltd, SleepTite, Stuart Therapeutics, TearClear*, and TECLens, Inc; has individual stocks in Harrow, Inc; and receives other funding (royalties) from Eye Therapies*.
Selina McGee, OD, is a consultant for AbbVie Inc, Aldeyra Therapeutics, Amgen Inc, Avellino, Bruder Healthcare, Cynosure, Dompé US, Inc, Eyevance, Harrow, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Optovue, Inc, Oyster Point Pharma, Inc, RVL Pharmaceuticals, Inc, ScienceBased Health, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Théa Pharma Inc, Topcon Medical Systems, Inc, Trukera, Versant Ventures, and Zeiss; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Cynosure, Dompé US, Inc, Lumenis, Optovue, Inc, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc.
Rishi P. Singh, MD, is a consultant for Alcon, Apellis Pharmaceuticals, Astellas Pharma Inc, Bausch & Lomb Incorporated, EyePoint Pharmaceuticals, Genentech, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, and Zeiss; and is a contracted researcher for Janssen Pharmaceuticals, Inc.
* The financial relationship existed during the past 24 months but has now ended
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 98458-PH (Asynchronous)
COPE Course Category: Pharmacology
Administrator: 
This activity, COPE Activity Number 130956, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Orasis Pharmaceuticals Inc for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, Orasis Pharmaceuticals Inc, or Review of Optometry.
This CE activity is copyrighted to MedEdicus LLC ©2025. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 337
Available Credit
- 1.50 COPE